The GEST MEETS VIRTUAL ON-DEMAND program is now available. Attendees who had pre-purchased the on-demand program and participated in the live program will be able to log in using the same credentials. For log in support please contact: firstname.lastname@example.org. Attendees wishing to access the on-demand program may purchase it via the link below.
The following financial relationships have been disclosed by the planners and faculty for this CME activity:
Upon completion of this activity, the learner should be able to:
Discuss the latest therapeutic options using embolization for interventional oncology, lymphatic interventions, musculoskeletal (MSK) applications, trauma, bariatric, hemorrhoid-related bleeding, pelvic congestion syndrome (PCS), varicocele, visceral aneurysms, endoleak, portal interventions, renal interventions, vascular malformations, trauma, critical care, women’s health, and men’s health
Assess standard and advanced imaging techniques for the various embolotherapy applications
Compare embolic and embolization options and understand the differences in function, characteristics and potential outcomes
Determine embolotherapy treatment vs other treatment options based on latest evidence, established patient care standards and multidisciplinary approaches
Explain anatomy, indications, contraindications, patient planning, and potential complications for embolization and interventional procedures
Formulate multidisciplinary treatment options for benign prostatic hyperplasia (BPH) and role of prostate artery embolization (PAE) with latest techniques.
Outline the details of artificial intelligence (AI) and/ or augmented reality (AR) with relation to assisting in embolization and interventional procedures.
Describe the role of immuno-oncology in relation to interventional oncology and other oncology specialties
GEST 2020 will be of value to interventional radiologists, oncologists, diagnostic radiologists, nurses, radiology technologists, physician assistants, and other healthcare professionals interested in the field of embolization.
Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Complete Conference Management designates this live activity for a maximum of 55 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.
Complete Conference Management makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Complete Conference Management must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an CCM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Complete Conference Management requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.